Once identified, ovarian tumors are usually surgically removed due to the presumed risk of complications associated with the diagnosis. Researchers recently looked to evaluate the incidence of cyst complications and malignancy during the first 2 years of follow-up after the tumors were classified as benign.
Once identified, ovarian tumors are usually surgically removed due to the presumed risk of complications associated with the diagnosis. Researchers recently looked to evaluate the incidence of cyst complications and malignancy during the first 2 years of follow-up after the tumors were classified as benign.
Study authors enrolled patients identified through the international prospective cohort International Ovarian Tumor Analysis Phase 5 (IOTA5) study who were older than 18 years with at least 1 ovarian tumor who had been selected for conservative management after an ultrasound assessment. Follow-up for patients was still ongoing at the time the study results were published.
In total, the study enrolled 1919 women from 10 different countries who had been diagnosed with noncancerous ovarian cysts. Researchers found that the cumulative incidence of spontaneous resolution of the cysts within 2 years of follow-up was 20.2% (95% CI, 18.4%-22.1%). Only 12 women were subsequently diagnosed with ovarian cancer, making the risk of malignancy 0.4% (95% CI, 0.1%-0.6%), although the authors cautioned that this could be due to a misdiagnosis of the tumors on the initial ultrasound scan. The rates of other complications, such as a torsion and a cyst rupturing, were 0.4% and 0.2%, respectively.
The study authors noted that these potential risks must be weighed against the risks of surgery, such as bowel perforation, which for women aged 50 to 74 years is between 3% to 5%.
Overall, the authors found that the “results suggest that the risk of malignancy and acute complications is low if [ovarian tumors] with benign ultrasound morphology are managed conservatively, which could be of value when counselling patients, and supports conservative management of [ovarian tumors] classified as benign by use of ultrasound.”
References
Froyman W, Landolfo C, deCock B, et al. Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicenter, prospective, cohort study [published February 5, 2019]. Lancet Oncol. doi: 10.1016/S1470-2045(18)30837-4.
Mirvetuximab Soravtansine-gynx Granted Full FDA Approval for FRα+ Platinum-Resistant Ovarian Cancer
March 22nd 2024Mirvetuximab soravtansine-gynx (Elahere) received full FDA approval for the treatment of folate receptor alpha–positive (FRα+), platinum-resistant ovarian cancer (PROC) based on findings from the confirmatory phase 3 MIRASOL trial.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Navigating the Mental Health Challenges of Cancer Diagnosis, Treatment, and Survivorship
March 12th 2024Stress has potential links to worse outcomes in cancer, such as decreased quality of life and greater risks of disease progression and metastasis. There is a complex mix of emotions patients with cancer experience.
Read More